Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

PRF Technologies Ltd.

$1.45

-0.14 (-8.75%)

Market Cap
1.26 M
EPS
-8.49
P/E Ratio
-
Value Trade
863.17 K
-6.88 %
Week
-40.64 %
1 Month
-54.15 %
3 Month
-64.46 %
6 Month
-99.95 %
5 Year
-99.98 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
201.79 K
52 Week Range
1.28 - 17.95
% held by Insiders
0 %
% held by Institutions
9.48 %
Enterprise Value
-2.14 M
Total Shares
844.46 K
Short %
40.97 %
Float Shares
764.23 K
Company Description
Employees:6
https://www.painreform.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
PRF-110 Post-operative pain (bunionectomy)
Phase 3
—
Small Molecules
-
PRF-110 Post-operative pain (bunionectomy)
Phase 3
—
Small Molecules
-
PRF-110 Post-operative pain (bunionectomy)
Phase 3
—
Small Molecules
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in PRFX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PRFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
PRFX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
PRFX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRFX
Jul 29, 2022
PRFXConferences/Events

Investor Presentation July 2022 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs a

Investor Presentation July 2022 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs and intentions . Forward - looking statements can be identif

Read more →
PRFX
Mar 8, 2021
PRFXGeneral

PainReform Announces $6.0 Million Private Placement

PainReform Announces $6.0 Million Private Placement HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics,

Read more →
PRFX
Jan 19, 2021
PRFXGeneral

NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2021 To the shareholders of PainReform Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of the sharehol

EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2021 To the shareholders of PainReform Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of the shareholders of PainReform Ltd. (the "Company") will be held at the offic

Read more →
PRFX
Jan 6, 2021
PRFXGeneral

PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations HERZLIYA, Israel - January 6, 2021 - PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established th

Read more →
PRFX
Jan 5, 2021
PRFXConferences/Events

Investor Presentation January 2021 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, belief

Investor Presentation January 2021 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs and intentions . Forward - looking statements can be iden

Read more →
PRFX
Jan 4, 2021
PRFXPhases

PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 Reports steady progress towards start of Phase 3 trial

PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 Reports steady progress towards start of HERZLIYA, Israel - January 4, 2021 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty

Read more →
PRFX
Nov 23, 2020
PRFXGeneral

PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer

Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer Israel - November 23, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of e

Read more →
PRFX
Nov 11, 2020
PRFXGeneral

PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors

PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors November 11, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation o

Read more →
PRFX
Nov 9, 2020
PRFXGeneral

PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors HERZLIYA, Israel - November XX, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a

PainReform Welcomes Senior Pharmaceutical Venture Capitalist Augustine Lawlor to Board of Directors November XX, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of establish

Read more →
PRFX
Oct 19, 2020
PRFXGeneral

PainReform Highlights Surgical Advantages of PRF-110 Studies demonstrate unique benefits of PRF-100 beyond analgesic activity PRF-110 addresses potential concerns in the local administration of anesthetic related to woun

PainReform Highlights Surgical Advantages Studies demonstrate unique benefits of PRF-100 beyond analgesic activity PRF-110 addresses potential concerns in the local administration of anesthetic related to wound healing and suture integrity that are commonly involved in surgi

Read more →
PRFX
Sep 30, 2020
PRFXGeneral

PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2020 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Balance Sheets 2 Condensed Statements of Comprehensive Loss 3 Condensed Statement of Changes in

FINANCIAL STATEMENTS DOLLARS IN THOUSANDS Page Condensed Balance Sheets 2 Condensed Statements of Comprehensive Loss 3 Condensed Statement of Changes in Convertible Preferred Shares and Shareholders' Deficit 4 Condensed Statements of Cash Flows 5 Notes to Condensed Financial S

Read more →
Competitive Position
How PRFX ranks across every disease it competes in
Competitive Position is a premium feature
See how PRFX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial